Leukemias | Clinical

Sabatolimab Demonstrates Promising Efficacy in Acute Myeloid Leukemia, Myelodysplastic Syndrome

January 02, 2021

In a phase 1b clinical trial presented during the 2020 American Society of Hematology Annual Meeting, investigators sought to determine the efficacy and safety of the novel TIM-3–targeting IgG4 antibody sabatolimab in combination with hypomethylating agents as treatment of patients with acute myeloid leukemia, as well as high-risk myelodysplastic syndrome.

Venetoclax Makes Inroads Into More Hematologic Setting

December 30, 2020

Expanding beyond the chronic lymphocytic leukemia/ small lymphocytic lymphoma space, the BCL2 inhibitor venetoclax garnered attention in 2020 for positive reports from phase 3 clinical trials exploring its use in acute myeloid leukemia and multiple myeloma.

Ponatinib Demonstrates Efficacy Over Time for Patients With CP-CML After Prior TKI Failure

December 07, 2020

High response rates and robust survival outcomes among patients with chronic-phase chronic myeloid leukemia who failed prior treatment with a second-generation tyrosine kinase inhibitor were observed in 2 clinical trials of ponatinib,.

Immunotherapy Treatment Improves Survival Among Adults With ALL After HCT Relapse

December 07, 2020

Adult patients with acute lymphoblastic leukemia who have relapsed following hematopoietic cell transplantation have experienced considerably improved survival benefits over the past few years, which may be due to an increased use of immunotherapy.

UCART22 Safe and Active in CD22-Expressing B-Cell ALLs

December 06, 2020

Early signs of clinical activity were observed in adult patients with relapsed/refractory CD22-positive B-cell acute lymphoblastic leukemia who were treated with an investigational allogeneic off-the-shelf CD22-directed therapy.